Prospective pivotal study of AADC gene therapy (AAV-hAADC gene therapy) in patients with aromatic L-amino acid decarboxylase (AADC) deficiency

Trial Profile

Prospective pivotal study of AADC gene therapy (AAV-hAADC gene therapy) in patients with aromatic L-amino acid decarboxylase (AADC) deficiency

Planning
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2016

At a glance

  • Drugs AAV-hAADC (Primary)
  • Indications Inborn error amino acid metabolic disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Agilis Biotherapeutics
  • Most Recent Events

    • 02 Mar 2016 According to an Agilis Biotherapeutics media release, this pivotal study in anticipated to begin in 2017.
    • 02 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top